Skip to main content

Compugen Reports Revenue Slide, Stagnant R&D, Narrowed Net Loss in Q3

NEW YORK, Oct. 24 - Compugen today said that a decrease in third-quarter revenue and stagnant R&D spending helped narrow net loss.

 

Revenue for the period ended Sept. 30 was $2.8 million, down from $3.1 million reported one year ago, Compugen said. Products and services accounted for $2.4 million of that (a decrease from the third quarter 2001), while income from R&D grants comprised around $460,000 (an increase over the same period last year).

 

R&D spending was virtually unchanged at $3.5 million, the company said. Still, net loss for the third quarter narrowed to $3.8 million, or $.11 per share, from $4.4 million, or $.14 per share, from the third quarter 2001.

 

Compugen said it had roughly $59 million in cash, cash equivalents, and short-term investments as of Sept. 30. It had $33.3 million in cash, cash equivalents, and short-term investments as of June 30.

 

Click here for more information.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.